Cim Investment Management Inc. Lowers Position in Medpace Holdings, Inc. $MEDP

Cim Investment Management Inc. trimmed its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 51.9% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 1,060 shares of the company’s stock after selling 1,142 shares during the quarter. Cim Investment Management Inc.’s holdings in Medpace were worth $545,000 at the end of the most recent quarter.

Several other institutional investors have also recently made changes to their positions in MEDP. Fifth Third Wealth Advisors LLC raised its stake in Medpace by 2.6% during the 3rd quarter. Fifth Third Wealth Advisors LLC now owns 737 shares of the company’s stock valued at $379,000 after purchasing an additional 19 shares during the period. BOKF NA boosted its stake in Medpace by 0.8% in the 3rd quarter. BOKF NA now owns 2,542 shares of the company’s stock worth $1,307,000 after purchasing an additional 20 shares during the period. HighPoint Advisor Group LLC boosted its stake in Medpace by 2.8% in the 3rd quarter. HighPoint Advisor Group LLC now owns 810 shares of the company’s stock worth $416,000 after purchasing an additional 22 shares during the period. Portside Wealth Group LLC grew its holdings in Medpace by 2.5% during the 2nd quarter. Portside Wealth Group LLC now owns 1,090 shares of the company’s stock valued at $342,000 after buying an additional 27 shares in the last quarter. Finally, Whittier Trust Co. of Nevada Inc. grew its holdings in Medpace by 35.1% during the 3rd quarter. Whittier Trust Co. of Nevada Inc. now owns 104 shares of the company’s stock valued at $55,000 after buying an additional 27 shares in the last quarter. Institutional investors own 77.98% of the company’s stock.

Analyst Ratings Changes

Several research firms have recently commented on MEDP. TD Cowen raised shares of Medpace from a “sell” rating to a “hold” rating and lowered their target price for the stock from $462.00 to $419.00 in a report on Wednesday, February 18th. Mizuho set a $582.00 target price on shares of Medpace in a research report on Wednesday, February 11th. BMO Capital Markets reaffirmed a “market perform” rating on shares of Medpace in a research note on Wednesday, February 11th. Leerink Partners reduced their price target on shares of Medpace from $575.00 to $485.00 and set a “market perform” rating on the stock in a report on Wednesday, February 11th. Finally, Robert W. Baird upgraded shares of Medpace from a “neutral” rating to an “outperform” rating and set a $564.00 price target on the stock in a research note on Tuesday, February 10th. Five research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $486.67.

Medpace Stock Up 0.3%

Medpace stock opened at $455.15 on Wednesday. The firm has a market cap of $12.92 billion, a P/E ratio of 29.75, a P/E/G ratio of 2.17 and a beta of 1.44. The business has a fifty day moving average of $517.88 and a two-hundred day moving average of $539.13. Medpace Holdings, Inc. has a twelve month low of $250.05 and a twelve month high of $628.92.

Medpace (NASDAQ:MEDP) last announced its quarterly earnings results on Monday, February 9th. The company reported $4.67 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $4.18 by $0.49. The business had revenue of $708.45 million for the quarter, compared to the consensus estimate of $689.53 million. Medpace had a return on equity of 118.82% and a net margin of 17.83%.The business’s revenue was up 32.0% compared to the same quarter last year. During the same period last year, the business posted $3.67 EPS. Medpace has set its FY 2026 guidance at 16.680-17.500 EPS. Equities analysts expect that Medpace Holdings, Inc. will post 12.29 earnings per share for the current year.

About Medpace

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.